Global Summit Hears Pledges To Cut Pandemic Vaccine Development Times
Cooperation Is Key To Tackling Health Threats
Is a 100-day timeline for developing vaccines against newly identified health threats a realistic proposition? Attendees at this week’s Global Pandemic Preparedness Summit certainly think so. Meanwhile, Moderna has said it will build its first African mRNA plant in Kenya, and has pledged “never” to enforce its vaccine patents in lower-income countries.
You may also be interested in...
Numerous initiatives are under way to maximize equitable access to COVID-19 products around the world, but most have some drawbacks that need to be addressed if they are to meet their goals, according to the medicines access NGO, WEMOS.
In the run-up to a major pandemic preparedness summit in London next month, CEPI has announced a new trial aimed at broadening access to vaccines in lower-income countries and has welcomed fresh funding for its plan to cut vaccine development times to 100 days.
Alvea, a US biotech startup, says its first two DNA vaccine candidates are undergoing “rigorous” preclinical testing and could enter clinical trials as early as April this year.